Brandywine Global Investment Management LLC Has $14.55 Million Position in United Therapeutics Corporation $UTHR

Brandywine Global Investment Management LLC grew its position in United Therapeutics Corporation (NASDAQ:UTHR) by 11.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 29,870 shares of the biotechnology company’s stock after buying an additional 3,080 shares during the period. Brandywine Global Investment Management LLC’s holdings in United Therapeutics were worth $14,554,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Torren Management LLC bought a new position in shares of United Therapeutics in the 4th quarter valued at about $26,000. Activest Wealth Management grew its position in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the period. Entrust Financial LLC bought a new position in shares of United Therapeutics in the 4th quarter valued at about $31,000. Wilmington Savings Fund Society FSB grew its position in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares during the period. Finally, Harbor Capital Advisors Inc. bought a new position in shares of United Therapeutics in the 4th quarter valued at about $48,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $544.69 on Tuesday. The company has a market capitalization of $23.12 billion, a price-to-earnings ratio of 20.11, a PEG ratio of 1.79 and a beta of 0.57. The company has a 50-day simple moving average of $568.47 and a 200 day simple moving average of $519.64. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the firm posted $6.63 EPS. Sell-side analysts forecast that United Therapeutics Corporation will post 26.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Raymond James Financial assumed coverage on shares of United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective for the company. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research report on Thursday, May 7th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Oppenheimer lifted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Finally, Bank of America lifted their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $547.07, for a total value of $4,540,681.00. Following the completion of the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at $24,712,246.04. The trade was a 15.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $547.62, for a total transaction of $5,202,390.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,185,729.06. This represents a 19.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 624,043 shares of company stock valued at $351,930,785 in the last quarter. Company insiders own 8.60% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.